# Amy Schulman

> Amy Schulman is a Series A investor at Lyndra Therapeutics backing Health Care. See 24 investments, check sizes, portfolio and contact details. Updated Aug…

- Type: Angel Investor
- Fund: Lyndra Therapeutics
- Location: Cambridge, United States
- Total investments: 24
- Last investment: Aug 2024
- Lead investor: 58%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/amy-schulman-107451a1

Amy Schulman is a Series A investor at Lyndra Therapeutics in Cambridge focused on Health Care and Biotechnology. Amy Schulman is based out of Indianapolis, Indiana and is the Managing Partner of Polaris Partners. Amy Schulman attended Wesleyan University.

## Contacts

5 contacts available for Amy Schulman: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/amy-w-schulman?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 11 | 46% |
| Biotechnology | 11 | 46% |
| Medical | 4 | 17% |
| Therapeutics | 4 | 17% |
| Wellness | 3 | 13% |

17 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 10 | 42% |
| Series B | 5 | 21% |
| Series C | 2 | 8% |
| Seed | 1 | 4% |
| Series D | 1 | 4% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 12 | 50% |
| Singapore | 1 | 4% |
| The Netherlands | 1 | 4% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Noetik | Noetik is an AI-native biotechnology company. Noetik leverages in advanced machine learning methods to discover and develop cancer immunotherapies. | $40M | Series A | Aug 28, 2024 |  |
| ByHeart | ByHeart operates as a fully integrated infant nutrition company. It is dedicated to translating leading nutrition science and breastmilk research into evolved foods and formulas to support babies’ health and parents’ peace of mind. Its products strive to be next to nature made from hand-picked ingredients using small-batch blending and sit at theforefront of immune, microbiome, cognitive, and digestive health.The company was founded in 2016 and is headquartered in New York. | $95M |  | May 13, 2024 |  |
| ByHeart | ByHeart operates as a fully integrated infant nutrition company. It is dedicated to translating leading nutrition science and breastmilk research into evolved foods and formulas to support babies’ health and parents’ peace of mind. Its products strive to be next to nature made from hand-picked ingredients using small-batch blending and sit at theforefront of immune, microbiome, cognitive, and digestive health.The company was founded in 2016 and is headquartered in New York. | $95M | Series C | May 13, 2024 |  |
| Vico Therapeutics | Vico Therapeutics is a developer of ribonucleic acid (RNA) modulating therapies for rare neurological disorders. The company discovers, develops, and delivers therapies for CNS disorders. Its initial focus is on SCA which is a subgroup of hereditary ataxia, HD which is a neurodegenerative disorder, and RTT-a neurodevelopmental disorder primarilyaffecting girls that enable clients with providing therapy for it.Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Judith van Deutekom, and Gail Mandel and it is headquartered in Leiden, The Netherlands. | $72.1M | Series B | Jan 05, 2024 |  |
| Engine Biosciences | Engine Biosciences is a biotech company that applies machine learning to genomics for drug discovery.Engine Biosciences is a venture-backed San Francisco- and Asia-based technology company pioneering network biomedicine. The company's proprietary and patented technologies oriented around deciphering the complexity of biology networks includeboth high-throughput wet lab experimentation and artificial intelligence algorithms for drug discovery and cellular reprogramming. This platform, developed through several years of research by our scientific founding and leadership team who include faculty members at MIT, Harvard, Mayo Clinic, and UCSD, dramatically accelerates and reduces costs of the R&D process for new medical therapies. We are actively applying the platform internally and with partners across a range of disease indications. | $27M | Series A | Oct 31, 2023 |  |
| Larkspur Biosciences | Larkspur's strategy focuses on the particular ways in which tumours hijack the immune system by developing precision immunotherapies for molecularly defined patient groups to overcome the bottlenecks that allow the tumour to subvert the immune system. | $35.5M | Series A | May 23, 2023 |  |
| Volastra Therapeutics | Volastra Therapeutics is a biotechnology company developing novel therapies for the treatment of metastatic cancers by exploiting unique insights into chromosomal instability | $60M | Series A | Mar 07, 2023 |  |
| Tessa Therapeutics | Tessa Therapeutics is a provider of therapy designed to focus on T cell therapy for solid tumors. The company's therapy specializes in developing virus specific T-cells and CAR T cells for the treatment of lymphoma, enabling healthcare providers to treat cancer patients and improve their lives. | $126M | Series A | Jun 09, 2022 |  |
| Thirty Madison | Thirty Madison is a virtual care company that provides treatment for chronic conditions. The company operates a portfolio of specialized brands that deliver personalized care and treatments. It partners with health plans and employers to provide its services as a covered benefit. | $140M | Series C | Jun 02, 2021 |  |
| Engine Biosciences | Engine Biosciences is a biotech company that applies machine learning to genomics for drug discovery.Engine Biosciences is a venture-backed San Francisco- and Asia-based technology company pioneering network biomedicine. The company's proprietary and patented technologies oriented around deciphering the complexity of biology networks includeboth high-throughput wet lab experimentation and artificial intelligence algorithms for drug discovery and cellular reprogramming. This platform, developed through several years of research by our scientific founding and leadership team who include faculty members at MIT, Harvard, Mayo Clinic, and UCSD, dramatically accelerates and reduces costs of the R&D process for new medical therapies. We are actively applying the platform internally and with partners across a range of disease indications. | $43M | Series A | May 26, 2021 |  |

10 of 24 investments shown.

## Co-investors
- [Droia Ventures](https://shizune.co/investors/profile/droia) — VC Fund, 7 deals together
- [Bellco Capital](https://shizune.co/investors/profile/bellco-capital) — VC Fund, 5 deals together
- [Catalio Capital Management](https://shizune.co/investors/profile/catalio-capital-management) — VC Fund, 5 deals together
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund, 4 deals together
- [Kurma Partners](https://shizune.co/investors/profile/kurma-life-science-partners) — VC Fund, 4 deals together
- [Temasek](https://shizune.co/investors/profile/temasek) — VC Fund, 4 deals together

## About Lyndra Therapeutics

VC Fund · Watertown, United States

Lyndra Therapeutics is reinventing medicines to make daily pills a thing of the past, replacing them with its oral, ultra-long-acting, sustained-release therapies. Administering and conveniently distributing medicines in weekly or longer-term doses – including using polypill approaches – will improve safety, efficacy, and adherence to maximizeglobal health impact and lower overall healthcare costs.

5 contacts available at Lyndra Therapeutics.

| Name | Title | Profile |
| --- | --- | --- |
| Amy Schulman | Executive Chairman & Co-Founder | — |
| Jessica Ballinger | COO | — |
| Klas Holmlund | Chief Financial Officer | — |
| Örn Almarsson | Chief Technology Officer | — |
| Patricia Hurter | CEO, President & Board Member | — |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Amy Schulman invest in?

Amy Schulman invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Series B stage. Most of the 24 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Amy Schulman?

Public channels for Amy Schulman include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Amy Schulman last invest?

The most recent investment recorded for Amy Schulman closed in Aug 2024. Shizune tracks 24 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co